We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
You can find your saved items on your dashboard, in the "saved" tab.
You've recommended your first item
Your recommendations help us improve our content suggestions for you and other PracticeUpdate members.
You've subscribed to your first topic alert
What does that mean?
Each day, we'll check to see if new items have been published to the topics you're subscribed to, and we'll send you one email with all of the new items from that day.
We'll keep all topic alert notifications available on your dashboard for 30 days, to make sure you don't miss anything.
Lastly, whenever you have unread items in the topics you've subscribed to, the "Alerts" icon will light up in the main menu. Just click on the bell to see your five most-recent, unread notifications.
This study examined patient characteristics and adverse outcomes in patients with type 1 diabetes (T1D) and COVID-19. COVID-19–positive patients (n=33) and patients exhibiting COVID-19–like symptoms (n=31) were included in the study. In the COVID-19–positive group, the most prevalent presenting symptoms were high blood glucose, elevated temperature, dry cough, excess fatigue, vomiting, shortness of breath, nausea, and body aches/headaches. The most prevalent adverse outcome was diabetic ketoacidosis (DKA). In the COVID-19–like symptom group, the most common presenting symptoms were similar to those in the COVID-19–positive group, and the most common adverse effect was DKA.
The most common presenting symptom for patients with T1D and COVID-19 was hyperglycemia, and the most common adverse effect was DKA. Further studies are needed to evaluate risk factors and outcomes in specific patient populations.
This abstract is available on the publisher's site.
The Centers for Disease Control and Prevention states that individuals with diabetes are at higher risk for severe illness with coronavirus disease 2019 (COVID-19) and poorer health outcomes (1). Research suggests the underlying reason for an increased risk of COVID-19 complications in individuals with diabetes may be poor glycemic control or hyperglycemia (2). Information on clinical outcomes for patients with type 1 diabetes who have confirmed cases of COVID-19 is limited. To our knowledge, this is the first U.S.-based multicenter study that addresses these questions in a population with type 1 diabetes.
This study aimed to examine patient characteristics and adverse outcomes among patients with type 1 diabetes with confirmed COVID-19. As a secondary objective, we investigated patient attributes and clinical outcomes in people with COVID-19–like symptoms for whom testing was unavailable or results were pending.